How do primary (testicular) and secondary (central) hypogonadism differ in pathophysiology, diagnosis, and treatment?

Primary vs Secondary Hypogonadism: Key Differences

Primary and secondary hypogonadism differ fundamentally in their site of dysfunction, with primary hypogonadism caused by testicular failure (hypergonadotropic) and secondary hypogonadism resulting from hypothalamic-pituitary-gonadal (HPG) axis impairment (hypogonadotropic), which critically determines both diagnostic approach and treatment strategy, particularly regarding fertility preservation. 1

Pathophysiology

Primary (Hypergonadotropic) Hypogonadism

• Testicular dysfunction is the primary defect, resulting in inadequate testosterone production despite elevated gonadotropins (LH and FSH) 1, 2
• The hypothalamus and pituitary attempt to compensate by increasing gonadotropin secretion, but the damaged testes cannot respond adequately 2
• Both Leydig cells (testosterone production) and Sertoli cells (spermatogenesis) may be affected 3

Common causes include: 1

• Klinefelter syndrome and other chromosomal abnormalities
• Chemotherapy, radiation, or testicular trauma
• Orchitis (mumps, HIV)
• Cryptorchidism
• Myotonic dystrophy
• Sickle cell disease

Secondary (Hypogonadotropic) Hypogonadism

• HPG axis dysfunction at the hypothalamic or pituitary level results in inadequate gonadotropin secretion, leading to reduced testicular stimulation 1
• Testosterone levels are low with inappropriately low or normal LH/FSH levels 2, 4
• The testes remain capable of responding to gonadotropin stimulation if provided 5

Common causes include: 1

• Idiopathic hypogonadotropic hypogonadism (including Kallmann syndrome)
• Pituitary adenomas or other tumors
• Hyperprolactinemia
• Traumatic brain injury
• Pituitary surgery or radiation
• Drug-induced: opiates, anabolic steroids, GnRH agonists/antagonists, glucocorticoids 1
• Obesity and metabolic syndrome (functional hypogonadism) 1

Diagnostic Approach

Initial Evaluation (Both Types)

• Morning total testosterone levels measured on two separate occasions to confirm biochemical deficiency 1, 4
• Presence of hypogonadism-consistent symptoms: reduced libido, erectile dysfunction, decreased energy, reduced muscle mass, hot flushes 1
• Avoid testing during acute illness, as this can spuriously lower testosterone 1
• Assess BMI, waist circumference, and screen for metabolic comorbidities 1

Distinguishing Primary from Secondary

Measure LH and FSH levels: 2, 4

• Primary hypogonadism: Elevated LH and FSH (hypergonadotropic)
• Secondary hypogonadism: Low or inappropriately normal LH and FSH (hypogonadotropic)

Additional Testing Based on Type

For Primary Hypogonadism: 1

• Karyotype if Klinefelter syndrome suspected (small, firm testes)
• Testicular ultrasound if structural abnormality suspected
• Screen for drugs/substances interfering with testosterone production
• Assess for metabolic diseases (obesity, metabolic syndrome, diabetes)

For Secondary Hypogonadism: 1

• Prolactin level to exclude hyperprolactinemia
• MRI of pituitary/hypothalamus if tumor or structural lesion suspected
• Assess other pituitary hormone axes if panhypopituitarism suspected
• Iron studies if hemochromatosis suspected
• Review medications that suppress HPG axis 1

Special Consideration: Functional Hypogonadism

• Diagnosed when no organic HPG axis alterations exist and low testosterone is primarily due to comorbidities (obesity, metabolic syndrome, type 2 diabetes) 1
• Treat underlying conditions first before considering testosterone therapy 1

Treatment Differences: The Critical Distinction

Primary Hypogonadism Treatment

Testosterone replacement therapy (TRT) is the only option, but it suppresses spermatogenesis and compromises fertility: 1, 5

• TRT formulations available: 5, 4

  • Testosterone gels (daily transdermal application)
  • Long-acting injectable testosterone (quarterly testosterone undecanoate or weekly/biweekly cypionate/enanthate)
  • Transdermal patches

• Critical limitation: TRT suppresses the HPG axis, reducing LH/FSH and further impairing any residual spermatogenesis 1, 6

• Fertility cannot be restored with medical therapy in most cases of primary hypogonadism 6

• Assisted reproductive technologies (testicular sperm extraction with ICSI) may be required for fertility 6

Secondary Hypogonadism Treatment

Treatment can potentially restore both testosterone levels AND fertility, making the distinction clinically crucial: 1, 5

For men desiring fertility or fertility preservation: 5, 6

• Human chorionic gonadotropin (hCG) stimulates Leydig cells to produce testosterone and maintains spermatogenesis
• Combined hCG and FSH therapy for men with severe hypogonadotropic hypogonadism
• GnRH pulsatile therapy for hypothalamic causes (less commonly used)
• Selective estrogen receptor modulators (SERMs) like clomiphene citrate can increase endogenous LH/FSH 5
• Aromatase inhibitors may be considered in select cases 5

For men NOT concerned with fertility: 5

• TRT can be used similarly to primary hypogonadism
• However, switching to gonadotropin therapy remains an option if fertility becomes desired later

Treatment of Underlying Causes

Secondary hypogonadism often requires addressing the primary etiology: 1

• Discontinue offending medications (opiates, anabolic steroids, glucocorticoids) when possible
• Treat hyperprolactinemia with dopamine agonists
• Surgical resection of pituitary tumors if indicated
• Weight loss and metabolic optimization for functional hypogonadism 1

Common Pitfalls

Diagnostic Pitfalls

• Failing to measure LH/FSH to distinguish primary from secondary forms, leading to inappropriate treatment selection 2, 4
• Testing testosterone during acute illness, which can cause transient suppression 1
• Not recognizing drug-induced secondary hypogonadism (especially opiates and anabolic steroids) 1
• Missing functional hypogonadism due to obesity/metabolic syndrome and initiating TRT without addressing underlying conditions 1

Treatment Pitfalls

• Starting TRT in men with secondary hypogonadism who desire fertility, permanently compromising their reproductive potential 1, 6
• Not screening for prostate cancer contraindications before initiating TRT in men >50 years 4
• Failing to monitor hematocrit during TRT (risk of polycythemia) 4
• Not recognizing that men with secondary hypogonadism have treatment options beyond TRT 5

Monitoring During Treatment

For all patients on TRT: 4

• Measure testosterone levels to confirm adequate replacement
• Annual hematocrit to detect polycythemia
• Digital rectal exam and PSA for prostate cancer screening in men >50 years (after discussing risks/benefits)
• Assess clinical response: sexual function, energy, body composition

For patients on gonadotropin therapy (secondary hypogonadism): 6

• Serial semen analyses to monitor spermatogenesis response
• Testosterone levels to ensure adequate replacement
• Treatment duration may extend 6-18 months before optimal sperm production achieved